Shares of RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) dropped 7.7% on Wednesday . The stock traded as low as $9.93 and last traded at $9.93. Approximately 500 shares changed hands during mid-day trading, a decline of 17% from the average daily volume of 600 shares. The stock had previously closed at $10.7550.
RemeGen Trading Down 7.7%
The stock’s fifty day moving average is $11.63 and its two-hundred day moving average is $7.36.
About RemeGen
RemeGen Co, Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers.
Featured Stories
- Five stocks we like better than RemeGen
- Large Cap Stock Definition and How to Invest
- Market Momentum: 3 Stocks Poised for Major Breakouts
- Best Energy Stocks – Energy Stocks to Buy Now
- 3 Reasons Casey’s General Stores Will Continue Trending Higher
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Golden Cross Alert: 3 Stocks With Major Upside Potential
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
